生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBB 生物科技指数ETF-iShares Nasdaq

交易中 08-28 13:42:09 EDT

209.38

-5.42

-2.52%

最高213.89	最低208.92	成交量84.58万
今开213.32	昨收214.80	日振幅2.31%
总市值104.69亿	流通市值104.69亿	总股本5,000万
成交额1.78亿	换手率1.69%	流通股本5,000万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":209.38,"timestamp":1787938926024,"preClose":214.8,"halted":0,"volume":845786,"delay":0,"changeRate":-0.02523277467411553,"floatShares":50000000,"shares":50000000,"eps":6.311863,"marketStatus":"交易中","change":-5.42,"latestTime":"08-28 13:42:09 EDT","open":213.32,"high":213.89,"low":208.92,"amount":178193129.35742,"amplitude":0.023138,"askPrice":209.42,"askSize":100,"bidPrice":209.37,"bidSize":22,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787947200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":214.8,"sharesOutstanding":50050000,"nav":215.209235,"aum":10803503597,"dividendRate":0.001953,"bidAskSpread":0.00038,"preHourTrading":{"tag":"盘前","latestPrice":213.5,"preClose":214.8,"latestTime":"09:16 EDT","volume":1784,"amount":383702.29183999996,"timestamp":1787923011851,"change":-1.3,"changeRate":-0.006052,"amplitude":0.015829},"postHourTrading":{"tag":"盘后","latestPrice":214.8,"preClose":214.8,"latestTime":"19:53 EDT","volume":53717,"amount":11538419.21,"timestamp":1787874807963,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.809402,"impliedVol":0.2242,"impliedVolPercentile":0.4064},"requestUrl":"/m/hq/s/IBB","defaultTab":"news","newsList":[{"id":"2662060177","title":"台裕制药提交针对HER2阳性乳腺癌的抗体药物偶联物生物类似药TSY-110的临床试验申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060177","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662060177?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:03","pubTimestamp":1787918605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731782.SGD","LU2322448957.HKD","LU1992135472.HKD","PPH","IBBQ","XPH","LU1992135399.USD","IBBJ","LU2473716301.USD","IE00B5TLWC47.USD","LU2272731865.HKD","MDTX","LU2322448791.USD","IBB","BMED","PSYK","LU2272731600.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146489142","title":"Tezspire®在嗜酸性食管炎III期临床试验中展现积极成果，共同主要终点及所有关键次要终点全面达标","url":"https://stock-news.laohu8.com/highlight/detail?id=1146489142","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146489142?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:00","pubTimestamp":1787810443,"startTime":"0","endTime":"0","summary":"Tezspire在针对嗜酸性食管炎的III期临床试验中取得了令人瞩目的积极结果。该试验不仅成功达到了共同主要终点，而且所有关键次要终点也悉数告捷。Tezspire的优异表现，标志着该领域治疗可能迎来重大变革。共同主要终点的同时达成，以及关键次要终点的全面覆盖，充分验证了Tezspire的疗效一致性和临床获益的广泛性。业内专家指出，Tezspire的这项研究成果，不仅巩固了其在炎症性疾病治疗领域的地位，更可能为后续的监管审批和市场推广奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2468319806.SGD","LU0122379950.USD","LU2089984988.USD","LU2242652126.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","LU1571399168.USD","BK4534","IE0002141913.USD","BK4581","IE0009355771.USD","BK4588","IE00BJJMRZ35.SGD","LU1057294990.SGD","PBE","PJP","TBXU","BIB","LU0289739699.SGD","LU1061106388.HKD","LU0109394709.USD","BK4139","BK4585","LU1023059063.AUD","LU0868494617.USD","IBB","AMGN","LU0058720904.USD","IBBQ","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4566","BK4533","LU2112291526.USD","BK4599","IE00BJT1NW94.SGD","LU0320765992.SGD","SG9999001440.SGD","BBH","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186632498","title":"欧盟委员会扩大吉利德Trodelvy®在转移性三阴性乳腺癌一线治疗中的应用范围，覆盖所有PD-L1状态","url":"https://stock-news.laohu8.com/highlight/detail?id=1186632498","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186632498?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:32","pubTimestamp":1787567559,"startTime":"0","endTime":"0","summary":"欧盟委员会近日作出重要决定，将吉利德科学（Gilead Sciences）旗下重磅药物Trodelvy®的适用范围进一步拓宽。此次调整聚焦于转移性三阴性乳腺癌的一线治疗领域，且不再受限于患者的PD-L1表达状态。这一举措意味着，无论生物标志物检测结果如何，符合条件的患者均有望从该疗法中获益。此举不仅为临床医生提供了更为灵活的用药选择，也标志着Trodelvy®在肿瘤治疗版图中的地位得到显著提升。吉利德科学方面对此表示积极回应，认为该批准将助力满足更多患者未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B3T34201.USD","IBBQ","LU0058720904.USD","LU0823416689.USD","LU0965509010.AUD","BK4532","LU0965509283.SGD","LU1585245621.USD","LU1934455194.USD","LU1674673428.USD","LU1061106388.HKD","LU2087621335.USD","LU1057294990.SGD","BK4550","BK4588","LU0109394709.USD","BK4578","LU1934455277.USD","LU0859254822.USD","MEDI","BBH","IBB","LU1066051498.USD","LU0882574055.USD","LU1037948541.HKD","GILD","IE00BSNM7G36.USD","BK4583","BK4566","BK4585","BIB","LU1674673691.USD","LU2357627491.SGD","LU2468319806.SGD","LU0289739699.SGD","LU1934455863.HKD","SG9999015986.USD","TMED","IE00BKVL7J92.USD","LU0965508806.USD","BK4139","LU1430594728.SGD","LU1571399168.USD","SG9999015945.SGD","LU0889565916.HKD","SG9999015978.USD","LU2112291526.USD","BK4568","LU0234570918.USD","IE00B19Z3581.USD","LU0861579265.USD","LU0965509101.SGD","LU0122379950.USD","LU2324357040.USD","LU1778281490.HKD","LU1023059063.AUD","BMED","LU1037948897.HKD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU1839511570.USD","LU0320765992.SGD","TBXU","LU1066053197.SGD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193380081","title":"吉利德科学：欧盟批准Trodelvy联合Keytruda用于一线PD-L1阳性转移性三阴性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1193380081","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193380081?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:32","pubTimestamp":1787567533,"startTime":"0","endTime":"0","summary":"吉利德科学公司宣布，欧盟已正式授予其抗体药物偶联物Trodelvy与默沙东的Keytruda联合用药方案的上市许可。这一批准针对的是既往未经治疗的PD-L1阳性转移性三阴性乳腺癌患者群体。此项授权标志着该联合疗法在欧盟地区的临床可及性迈出关键一步，为这类侵袭性强、治疗选择有限的乳腺癌亚型患者提供了新的一线治疗选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","LU0058720904.USD","LU1037948897.HKD","LU1934455863.HKD","LU2089984988.USD","TMED","BK4550","BK4583","LU2112291526.USD","LU1585245621.USD","LU1934455277.USD","LU2357627491.SGD","BK4585","LU1674673691.USD","LU1037948541.HKD","LU0122379950.USD","LU1023059063.AUD","BK4568","IE0002270589.USD","BBH","IE00B3T34201.USD","LU0109394709.USD","SG9999015986.USD","BK4578","SG9999015952.SGD","LU0859254822.USD","LU0965508806.USD","LU0965509101.SGD","SG9999015945.SGD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0234570918.USD","BIB","SG9999015978.USD","LU2468319806.SGD","LU0114720955.EUR","LU0965509283.SGD","BK4588","IE00B19Z3B42.SGD","LU0889565916.HKD","IE00B19Z3581.USD","LU1778281490.HKD","BK4139","LU2324357040.USD","IE00BZ1G4Q59.USD","IBB","LU1057294990.SGD","LU2087621335.USD","MEDI","IE00B7SZLL34.SGD","BK4532","LU1934455194.USD","LU1674673428.USD","LU1571399168.USD","LU0882574055.USD","IBBQ","LU1061106388.HKD","LU1430594728.SGD","BMED","LU0823416689.USD","LU1839511570.USD","LU0289739699.SGD","IE00BKVL7J92.USD","BK4566","TBXU","GILD","LU0861579265.USD","LU1066051498.USD","LU0965509010.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250489","title":"Piper Sandler上调安进目标价至457美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250489","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661250489?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:20","pubTimestamp":1787296801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0109394709.USD","UUP","LU1023059063.AUD","LU2242646821.SGD","LU0122379950.USD","IBB","IE00B4R5TH58.HKD","LU0289739699.SGD","BK4581","BIB","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","IBBQ","IE00BJT1NW94.SGD","BBH","LU1983299246.USD","TBXU","PJP","BK4139","BK4585","LU2468319806.SGD","BK4566","LU2089984988.USD","LU0889565916.HKD","LU1061106388.HKD","SG9999001440.SGD","LU1057294990.SGD","LU2112291526.USD","PBE","BK4588","UDN","IE00B2B36J28.USD","BK4599","LU0058720904.USD","LU0868494617.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU2242652126.USD","BK4534","AMGN","IE0009355771.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660747701","title":"复宏汉霖盘中涨近8% 近期联手山德士出海至多10款生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=2660747701","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660747701?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:56","pubTimestamp":1787194560,"startTime":"0","endTime":"0","summary":"模拟交易客户端复宏汉霖盘中涨近8%，截至发稿，股价上涨6.87%，现报70.05港元，成交额1646.58万港元。基于上述首批约定，山德士将向复宏汉霖支付首付款、相关里程碑付款及不可退还的选择权费共计至高3.22亿美元；2026年，复宏汉霖预计可达成的开票金额总计不超过1.005亿美元。值得一提的是，海外市场已成为复宏汉霖业绩增长的重要组成部分。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-20/doc-ininxqxw2099208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XPH","PPH","BK4588","LU2322448957.HKD","BK4585","LU2473716301.USD","IE00B5TLWC47.USD","LU1992135472.HKD","IBB","02696","HK0000320223.HKD","LU2272731865.HKD","LU2322448791.USD","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","LU1992135399.USD","LU2272731600.USD","HK0000306701.USD","BK1161","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105025052","title":"再生元制药旗下Pasatru获欧洲药品管理局审评，全球申报在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025052","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105025052?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:00","pubTimestamp":1787162410,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发的药物Pasatru已被欧洲药品管理局纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","TBXU","LU0889565916.HKD","BBH","LU2237438978.USD","IBBQ","LU0320765992.SGD","LU2023250504.SGD","LU1917777945.USD","LU0882574055.USD","IBB","LU0823416689.USD","BK4585","LU0114720955.EUR","BK4139","REGN","LU2089984988.USD","LU2362540622.SGD","LU0289739699.SGD","LU0053666078.USD","LU0058720904.USD","LU2362541273.HKD","LU2468319806.SGD","BK4588","LU0109394709.USD","LU2362541513.USD","LU0823434740.USD","LU1974910355.USD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188134905","title":"再生元制药获FDA批准：Pasatru（Garetosmab-Grts）上市，治疗成人进行性骨化性纤维发育不良","url":"https://stock-news.laohu8.com/highlight/detail?id=1188134905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188134905?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:59","pubTimestamp":1787162353,"startTime":"0","endTime":"0","summary":"再生元制药公司今日宣布，其研发的新药Pasatru已获得美国食品药品监督管理局的正式批准，用于治疗成人进行性骨化性纤维发育不良。这一罕见疾病此前一直缺乏有效的治疗手段，此次获批为患者带来了新的希望。FDA的此次批准基于多项临床研究数据，结果显示Pasatru在减缓异位骨化进展方面表现出显著疗效，且安全性可控。未来，再生元制药计划进一步拓展Pasatru的适应症范围，并探索其在其他相关疾病中的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0889565916.HKD","IBB","BK4588","LU0320765992.SGD","LU0114720955.EUR","LU1974910355.USD","LU2362541513.USD","LU2106854487.HKD","BK4139","LU0289739699.SGD","LU1917777945.USD","LU0823434583.USD","LU0058720904.USD","REGN","IBBQ","LU2023250504.SGD","BK4585","LU0823434740.USD","LU2362540622.SGD","TBXU","LU0882574055.USD","LU0053666078.USD","LU0109394709.USD","LU0823416689.USD","BBH","LU2237438978.USD","LU2468319806.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187101531","title":"异动解读｜生物科技指数ETF-iShares Nasdaq盘中上涨5.1%，MNC并购加速叠加多重利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1187101531","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187101531?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:09","pubTimestamp":1787148587,"startTime":"0","endTime":"0","summary":"8月19日，生物科技指数ETF-iShares Nasdaq盘中上涨5.1%，报213.88美元，成交额1.03亿美元。消息面上，生物科技板块近期迎来多重利好共振。另一方面，AI制药订单持续落地驱动生命科学上游需求攀升，板块整体景气度回暖。此外，再生元Libtayo获加拿大卫生部批准用于高危皮肤鳞状细胞癌辅助治疗，进一步提振市场情绪。该ETF追踪纳斯达克生物医疗指数，包含在纳斯达克上市的生物医疗公司，成分和权重可能随时间变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660585446","title":"瑞穗上调安进目标价至352美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660585446","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660585446?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:55","pubTimestamp":1787129710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IBBQ","LU1571399168.USD","UDN","IE0002141913.USD","BK4533","IE00BJT1NW94.SGD","SG9999001440.SGD","BK4534","LU2112291526.USD","BK4588","LU0122379950.USD","LU2089984988.USD","PBE","UUP","BBH","PJP","LU0109394709.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU1057294990.SGD","LU0889565916.HKD","BK4599","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0868494617.USD","BK4139","BIB","TBXU","LU1061106388.HKD","IE0009355771.USD","BK4581","LU0289739699.SGD","BK4566","IBB","BK4585","LU2242646821.SGD","AMGN","LU0320765992.SGD","IE00B2B36J28.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431564","title":"骏利亨德森投资：专利到期倒逼药企扩张 生物科技并购、IPO市场同步复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431564","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431564?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:06","pubTimestamp":1787126785,"startTime":"0","endTime":"0","summary":"骏利亨德森投资称，尽管利率较市场年初的预期为高，但生物科技行业交易活动的增长动力持续不减。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","BK4582","FBT","SPCK","BIS","IAI","BBP","GTPE","MRNX","IBBJ","JDOC","MRNY","IJT","BBC","QSML","BK4585","BIB","IWO","PBE","IYG","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安进将终止与其研究合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192416297?lang=zh_cn&edition=full","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","PJP","TCRX","SG9999001440.SGD","LU0320765992.SGD","LU2242646821.SGD","BK4585","BIB","IE0002141913.USD","TBXU","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","IE00BJJMRZ35.SGD","BK4599","LU1061106388.HKD","IBB","BBH","LU0868494617.USD","LU1023059063.AUD","LU1983299246.USD","LU2242652126.USD","LU0889565916.HKD","LU2112291526.USD","LU0109394709.USD","BK4139","BK4581","LU0058720904.USD","LU0122379950.USD","BK4539","BK4588","BK4566","IE00BJT1NW94.SGD","BK4534","LU2089984988.USD","AMGN","BK4533","IBBQ","IE0009355771.USD","LU1057294990.SGD","LU0289739699.SGD","PBE","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137019504","title":"美股开盘 | 三大指数涨跌不一，闪迪涨超3%，Argenx SE涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137019504","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137019504?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:32","pubTimestamp":1786973544,"startTime":"0","endTime":"0","summary":"8月17日，美股三大指数开盘涨跌不一，道琼斯指数跌0.23%，标普500指数涨0.04%，纳斯达克综合指数涨0.24%。美股存储股普涨，SK海力士、西部数据、闪迪涨超3%，美光科技、希捷科技涨超2%。OmniAb涨超23%，公司此前宣布与礼来达成3.7亿美元药物研发协议。Argenx SE涨近9%，Efgartigimod治疗肌炎III期试验成功。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","SPXU","SGXZ99366536.SGD","LU0082616367.USD","LU0079474960.USD","LU0385154629.USD","LU2471134879.HKD","LU0476273544.USD","LU2403377893.USD","IXJ","IE0001KFT4U8.USD","LU1127390331.HKD","LU1814569148.SGD","SMU00main","LU0889565916.HKD","USXF","SPXS","FXL","LU0683600562.USD","LU0122379950.USD","IE00B19Z9P08.USD","LU2360106947.USD","FTXL","LU2552382132.HKD","LU1023059063.AUD","LU1852331112.SGD","EGGY","LU2063271972.USD","TRFK","TBXU","LU0106261372.USD","LU2361044865.SGD","TRUH","LU0719512351.SGD","TMED","SMAX","IE00BKPKM429.USD","DIA","LU2089284900.SGD","LU2028103732.USD","BK4512","SG9999014880.SGD","ELIL","LU0859254822.USD","LU2750360641.GBP","LU2264538146.SGD","LU2471134523.USD","LU2552382058.USD","LU0786609619.USD","SPY","LU1035775433.USD","LU0266013472.USD","LU2089984988.USD","LU2462157665.USD","SPXL","SCHM","MEDI","IE0034235303.USD","LU0210536198.USD","LU0471298777.SGD","CGGO","LU0672654240.SGD","BK4170","LU2286300806.USD","LU1914381329.SGD","IE00BFSS8Q28.SGD","LEGR","LU2458330243.SGD","LU0957808578.USD","BK4579","QQQA","LU2237443382.USD","LU2750360997.AUD","LU0203202063.USD","IE00B7SZLL34.SGD","LU0240877869.USD","PPH","LU2237438978.USD",".DJI","LU1989764748.USD","LU1861220033.SGD","SKDD","BK4516","IE0005OL40V9.USD","LU0456855351.SGD","SG9999001176.SGD","LU2236285917.USD","LU2543165471.USD","BK4599","SG9999014914.USD","LU0320765059.SGD","LU1983299246.USD","IXN","CHPX","BK4553","LU0471298694.HKD","LU2458330169.SGD","IE00BN29S564.USD","LU0109392836.USD","LU0061475181.USD","LU1280957306.USD","LU1979441026.SGD","LU0345770308.USD","SK","LU1267930813.SGD","LU2471134796.USD","LU0174119429.USD","BK7142","LU2237443465.HKD","HRTS","LU2089283258.USD","LU1674673691.USD","LU0964807845.USD","BOBP","LU2168564149.EUR","LU0963586101.USD","LU0889565833.HKD","IETC","IE00BJLML261.HKD","LU1035773651.USD","LU0054578231.USD","THNR","IE00B1XK9C88.USD","ARGX","WDC","LU1145028129.USD","LU2491049909.HKD","LU1861215975.USD","LU2023250504.SGD","LU2108987350.USD","VHT","LU0642271901.SGD","LU0823434583.USD","LU2237443549.SGD","LU2250418816.HKD","LU0127658192.USD","BK4141","LU1815336760.USD","LU1093756168.USD","LU2756315664.SGD","IE00BSNM7G36.USD","IE00B2B36J28.USD","BK4532","LU2023251221.USD","LU1629891620.HKD","LU2896262040.SGD","SOXX","LU0689472784.USD","DDM","IE00BWXC8680.SGD","LLY","LU0234572021.USD","LU1868836914.USD","LU0072461881.USD","LU1989771016.USD","LU0444971666.USD","LU2357305700.SGD","COWG","IE00B7KXQ091.USD","IE00B19Z9Z06.USD","LU1323610961.USD","SG9999018865.SGD","LU2360107168.USD","SPYQ","LU0114720955.EUR","CANC","IE0004445015.USD","LU1623119135.USD","IE00B5949003.HKD","IE0034235188.USD","EFIV","LU2102340556.USD","LU0640476718.USD","YMmain","JDOC","LU2237443622.USD","HIBL","LU0345770993.USD","SG9999015952.SGD","LU0058720904.USD","LU0158827781.USD","LU2211815571.USD","LU2746668461.USD","MIC","BK4605","CHPS","LU1917777945.USD","BK4534","LU0056508442.USD","LU1712237335.SGD","LU0316494557.USD","SG9999014906.USD","LU1093756325.SGD","LU2168564222.USD","07709","SKHX","IE0002141913.USD","RULE","LU1989764664.SGD","LU1670628061.USD","LU0823416689.USD","LU2324357040.USD","LU1235294995.USD","SOXQ","SHOC","LU0157215616.USD","SNDU","LU2168564065.EUR","LU2462591350.SGD","LU0203347892.USD","HYNX","SG9999018857.SGD","LU0708995401.HKD","SKHYV","LU1868837136.USD","LU2746668974.SGD","MULL","STX","OZEM","UDOW","LU0466842654.USD","LU1778281490.HKD","RXL","LU0354030438.USD","LU0417517546.SGD","TTXU","OPTZ","XNTK","WDNA","LU2417539215.USD","IE00B19Z3581.USD","IE00BJJMRZ35.SGD","FSMD","LU1069347547.HKD","LU1366192091.USD","IE00BKDWB100.SGD","LU1642822529.SGD","LU2491050154.USD","MUD","LU1064131342.USD","LU0133085943.USD","LU1983260115.SGD","ELIS","CHAT","LU1720051108.HKD","LU0203201768.USD","CNEQ","IYH","LU2468319806.SGD","IE00B1BXHZ80.USD","SGXZ51526630.SGD","MMAX","IE00B4R5TH58.HKD","LU2471134952.CNY","LU2360106780.USD","SKHZ","SDOW","SMH","LU1803068979.SGD","LU0889566641.SGD","LU0256863811.USD","YSPY","IE00B4JS1V06.HKD","LU0943347566.SGD","LU0353189763.USD","LU0081259029.USD","LU0238689110.USD","LU0097036916.USD","LU0882574139.USD","LU1868837300.USD","LU2456880835.USD","SG9999015986.USD","SKHU","SGXZ57979304.SGD","ARTY","GDOC","IE00B775H168.HKD","MHIP","SSO","AIS","DXD","IE00B894F039.SGD","DMAX","LU0006061336.USD","STX.AU","LU0882574055.USD","BAI","LU2168564495.EUR","LU1291159041.SGD","IE0004445239.USD","SKUU","LU0109391861.USD","LU0353189680.USD","LU0289739699.SGD","SPUU","SPYM","LU0323591593.USD","LU2168563687.JPY","SG9999014898.SGD","LU0823434740.USD","SH","LU2491050071.SGD","LLII","LU0320765992.SGD","SG9999001176.USD","DRMY","BK4575","LU0158827948.USD","LU1868836757.USD","LU2111349929.HKD","WLDR","PJP","PSI","SGXZ81514606.USD","SPYU","BK4505","EMSF","SGXZ31699556.SGD","SNDC","XLK","IE00BJT1NW94.SGD","LLYX","QQQG","LU2271345857.HKD","IE00BJJMRX11.SGD","IE0009355771.USD","LU0792757196.USD","LU0225283273.USD","LU0274383776.USD","BK4554","AIFD","MU","IE0009356076.USD","LU1868836591.USD","IBB","GB00BDT5M118.USD","IE00BFTCPJ56.SGD","LU2265009873.SGD","LU0820561909.HKD","LU1551013425.SGD","LU0256863902.USD","LU0094547139.USD","FCUS","VOO","SPDN","VGT","LU1551013342.USD","LU0444973449.USD","SDS","AGNG","LU2213496289.HKD",".SPX","FDTX","LU2931357623.SGD","BK4588","LU1670627923.USD","LU0820561818.USD","LU0109394709.USD","SNDQ","BK4139","LU2552382215.SGD","IHE","LU1366333091.USD","BK4566","DISK","LU1988902786.USD","SKHA","MEDX","LU0096364046.USD","BK4527","WDCX","LU2602419157.SGD","IE00BK4W5L77.USD","AIQ","MUU","IE00BFSS7M15.SGD","LU2237443978.SGD","LU1974910355.USD","SG9999015945.SGD","LU2756315318.SGD","LU1069344957.HKD","IE00B19Z3B42.SGD","SG9999017495.SGD","LU0240878834.USD","LU0006306889.USD","PTF","LU2048586759.USD","CURE","SPYH","SKHY","FAI","SNDG","LU1267930730.SGD","LU2054465674.USD","FMED","DOG","TMSL","LU1232071149.USD","LU2106854487.HKD","LU1548497426.USD","XLV","LU2361044949.HKD","HBMX","WUGI","SG9999013999.USD","MUYY","LU0162691827.USD","FHLC","LLYZ","LU2089985449.USD","LU1046421795.USD","LU1316542783.SGD","UPRO","LU2237443895.HKD","LU1720051017.SGD","SG9999015978.USD","SNDK","LU2112291526.USD","LU0203345920.USD","BK4585","IE0002270589.USD","LU0354030511.USD","LU2087625088.SGD","LU2461242641.AUD","LU1823568750.SGD","LU0198837287.USD","JGRO","MUZ","LU1061106388.HKD","ILDR","LU2290526834.HKD","LU0154236417.USD","CNAV","IVV","BK4543","IE00BJJMRY28.SGD","LU0787776722.HKD","LU0432979614.USD","LU1804176565.USD","FTXH","LU2361045086.USD",".IXIC","BK4533","LU2023250330.USD","LU2357627491.SGD","BK4581","SNXX","LU1674673428.USD","LU1057294990.SGD","SG9999001424.SGD","BK4007","LU0820562030.AUD","SCHA","FTEC","IE00BK4W5M84.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股异动 | Argenx(ARGX.US)盘前涨超10% 自身免疫性肌炎药物Vyvgart III期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660481020?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765992.SGD","BK4139","IE0002141913.USD","IE00B4R5TH58.HKD","LU2324357040.USD","TBXU","BK4585","LU0889565916.HKD","BK4505","FMED","LU0823416689.USD","LU1983260115.SGD","IE0034235188.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4588","III","BK4134","ARGX","IBB","IE00BJT1NW94.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股异动丨Argenx SE盘前大涨超7%，Efgartigimod治疗肌炎III期试验成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660848605?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00B4R5TH58.HKD","BK4585","BK4505","LU0109394709.USD","LU1983260115.SGD","III","LU0320765992.SGD","TBXU","ARGX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","FMED","IE0034235188.USD","IE00BJJMRZ35.SGD","LU0823416689.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4588","LU0889565916.HKD","LU2324357040.USD","IE0002141913.USD","BK4139","BK4134","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660866704","title":"复星医药子公司携生物类似药出海 牵手全球仿制药龙头，锁定四成销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660866704?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日，复星医药（SH600196，股价24.01元，市值588.9亿元）公告披露，其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定，可就复宏汉霖至多10款单克隆抗体（mAb）和/或抗体偶联药物（ADC）生物类似药，开展海外区域的注册、商业化、开发、生产等许可合作，并已就首批3款产品达成具体商业条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","LU2473716301.USD","BK0060","BK1593","BK0012","IBB","BK0096","LU2272731865.HKD","BK0187","XPH","BK1191","BK0188","IE00B5TLWC47.USD","02196","BK0196","LU1992135472.HKD","PPH","LU2272731782.SGD","BK4585","600196","BK0028","BK0175","LU2322448791.USD","LU2272731600.USD","LU2322448957.HKD","BK4588","BK0239","BK1515","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660857514","title":"复宏汉霖与山德士达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660857514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660857514?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:05","pubTimestamp":1786957508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731865.HKD","XPH","LU2473716301.USD","IBB","PPH","LU2272731600.USD","BK4588","BK4585","IE00B5TLWC47.USD","LU1992135399.USD","LU2272731782.SGD","LU2322448957.HKD","LU2322448791.USD","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660853994","title":"argenx SE（ARGX）宣布Efgartigimod治疗自身免疫性肌炎的3期ALKIVIA试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660853994","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660853994?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:43","pubTimestamp":1786956188,"startTime":"0","endTime":"0","summary":"该试验评估了皮下注射药物VYVGART Hytrulo在成人自身免疫性肌炎中的疗效，包括免疫介导的坏死性肌病和皮肌炎。在IMNM亚组分析中，治疗组同样展现出14.8分的显著改善。这是全球首个在没有任何批准疗法的IMNM领域取得统计学显著与临床意义改善的三期临床试验。自身免疫性肌炎属于罕见且高度致残的疾病，长久以来临床严重依赖大剂量激素和广谱免疫抑制剂。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX","IE00BJT1NW94.SGD","FMED","IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","TBXU","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4505","IE00BJJMRZ35.SGD","BK4139","LU0823416689.USD","IE0009355771.USD","IE0034235188.USD","LU2324357040.USD","LU0320765992.SGD","IBB","LU0889565916.HKD","BK4588","BK4585","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101358","title":"巴克莱上调安进目标价至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660101358?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:05","pubTimestamp":1786935953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","LU0058720904.USD","IBB","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU0122379950.USD","BK4588","UDN","IE00B4R5TH58.HKD","PJP","IE00BJJMRZ35.SGD","LU2242652126.USD","TBXU","SG9999001440.SGD","BBH","LU1061106388.HKD","AMGN","LU1571399168.USD","BK4581","BK4566","UUP","LU1057294990.SGD","BIB","IE0002141913.USD","LU0289739699.SGD","IBBQ","BK4599","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU0320765992.SGD","LU2242646821.SGD","LU2468319806.SGD","LU2112291526.USD","LU0109394709.USD","PBE","BK4534","LU1983299246.USD","IE0009355771.USD","BK4139","LU0868494617.USD","BK4533","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106203","title":"复宏汉霖拟向山德士授权至多10款生物类似药，国产生物药国际化再进一步｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106203","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660106203?lang=zh_cn&edition=full","pubTime":"2026-08-17 09:33","pubTimestamp":1786930438,"startTime":"0","endTime":"0","summary":"过去一周（截至8月14日收盘），创新药板块震荡上行。打包医药全产业链的医药ETF（512120）上涨0.2%，聚焦A股创新药的生物医药ETF（159508）上涨1.77%，聚焦港股创新药的港股通生物科技ETF（159102）上涨0.12%。相关个股中，康龙化成上涨8.48%、药明康德上涨2.85%、恒瑞医药下跌3.66%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842706171.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842706171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XPH","LU2272731782.SGD","BK4588","IBB","IE00B5TLWC47.USD","LU1992135399.USD","HK0000320264.USD","LU2272731865.HKD","LU2272731600.USD","HK0000165453.HKD","09939","BK1515","LU2322448791.USD","HK0000306685.HKD","HK0000306701.USD","BK1574","LU2322448957.HKD","LU2473716301.USD","PPH","BK1161","159938","159839","HK0000320223.HKD","BK4585","LU1992135472.HKD","02696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.1274},{"period":"3month","weight":0.2475},{"period":"6month","weight":0.2248},{"period":"1year","weight":0.5499},{"period":"ytd","weight":0.2727}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0408},{"period":"3month","weight":0.0193},{"period":"6month","weight":0.1241},{"period":"1year","weight":0.1925},{"period":"ytd","weight":0.1308}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安硕纳斯达克生物科技ETF追踪纳斯达克生物医疗指数(Biotechnology Index)。Biotechnology Index包含的标的为在纳斯达克上市的生物医疗公司。\n风险提示：标的成分和权重，有可能随着时间的迁移而发生变化。","yearOnYearQuotes":[{"month":1,"riseRate":0.722222,"avgChangeRate":0.019108},{"month":2,"riseRate":0.611111,"avgChangeRate":-0.001245},{"month":3,"riseRate":0.555556,"avgChangeRate":0.002788},{"month":4,"riseRate":0.5,"avgChangeRate":0.003638},{"month":5,"riseRate":0.611111,"avgChangeRate":0.009102},{"month":6,"riseRate":0.777778,"avgChangeRate":0.027534},{"month":7,"riseRate":0.722222,"avgChangeRate":0.03565},{"month":8,"riseRate":0.5,"avgChangeRate":0.007806},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.000938},{"month":10,"riseRate":0.388889,"avgChangeRate":-0.014563},{"month":11,"riseRate":0.833333,"avgChangeRate":0.040881},{"month":12,"riseRate":0.555556,"avgChangeRate":0.007272}],"exchange":"NASDAQ","name":"生物科技指数ETF-iShares Nasdaq","nameEN":"iShares Biotechnology ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技指数ETF-iShares Nasdaq,IBB,生物科技指数ETF-iShares Nasdaq股票,生物科技指数ETF-iShares Nasdaq股票老虎,生物科技指数ETF-iShares Nasdaq股票老虎国际,生物科技指数ETF-iShares Nasdaq行情,生物科技指数ETF-iShares Nasdaq股票行情,生物科技指数ETF-iShares Nasdaq股价,生物科技指数ETF-iShares Nasdaq股市,生物科技指数ETF-iShares Nasdaq股票价格,生物科技指数ETF-iShares Nasdaq股票交易,生物科技指数ETF-iShares Nasdaq股票购买,生物科技指数ETF-iShares Nasdaq股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}